AZD-5991 S-enantiomer, the S-enantiomer of AZD-5991, is the less active enantiomer of AZD-5991. AZD-5991 S-enantiomer is a Mcl-1 inhibitor with an IC50 of 6.3 μM in FRET assay and a Kd of 0.98 μM in surface plasmon resonance (SPR) assay.

Avelumab (Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C; trade name Bavencio) is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity. It is developed by Merck KGaA and Pfize as a pharmaceutical drug for use in immunotherapy, originally for the treatment of non-small-cell lung carcinoma (NSCLC). Avelumab targets the protein programmed death-ligand […]

AZD-2066 is a potent, selective, orally bioavailable and brain penetrant antagonist mGlu5 (metabotropic glutamate receptor 5) with IC50 in the nanomolar range for rat and human receptors, respectively. It displays discriminative effects in rats. The discriminative effects of AZD9272 and AZD2066 are similar to those of previously investigated mGluR5 antagonists and dissimilar to those of […]

Macimorelin acetate (formerly AEZS-130; EP-1572; JMV-1843; trade name: Macrilen), the acetate salt form of Macimorelin, is a novel and potent synthetic small molecule growth hormone secretagogue receptor agonist approved in 2018 for use in the diagnosis of adult growth hormone deficiency. As a ghrelin agonist, it is orally active and stimulates the secretion of growth […]

Indacrinone (MK196; Indacrynic acid; Indanone) is an investigational loop diuretic which can be used in patients of gout with hypertension as an antihypertensive because it decreases reabsorption of uric acid. It has pronounced saluretic activity in the rat and dog as well as both uricosuric and saluretic activity in the chimpanzee.

Cetuximab (C225; C 225; C-225; Erbitux) is a potent and specific chimeric monoclonal antibody approved for cancer treatment. It inhibits epidermal growth factor receptor (EGFR) with a Kd of 0.201 nM for soluble EGFR by SPR. Cetuximab has potent antitumor activity and has been approved for use in the treatment of metastatic colorectal cancer, metastatic […]

MK-6913 (also known as Tetrahydrofluoroene 52) is a novel, potent and selective estrogen receptor β agonist.

OPC-167832 (OPC167832) is a novel carbostyril derivative developed by Otsuka with potent antituberculosis activity, acting as a DprE1 (decaprenylphosphoryl-β-d-ribose 2′-oxidase) Inhibitor. In a mouse model of chronic TB, OPC-167832 showed potent bactericidal activities starting at a dose of 0.625 mg/kg of body weight. Further, it exhibited significant combination effects in 2-drug combinations with delamanid, bedaquiline, or […]

Benzamide HCl is a potent FTO inhibitor with the potential to be used for treating obesity, breast cancers, pancreatic cancer, and Alzheimer’s diseases.

Besifovir (formerly known as ANA-380; LB-80380; PMCDG dipivoxil; Korea Trade name: Besivo) is a reverse transcriptase inhibitor that has been approved in Korea to treat hepatitis B virus (HBV) infection. It is a novel and potent acyclic nucleotide phosphonate with a similar chemical structure to adefovir and tenofovir. Besifovir is a prodrug and an oral […]